Drop Down MenusCSS Drop Down MenuPure CSS Dropdown Menu
Alternative Text Alternative Text Alternative Text Alternative Text
Survivor of US Drone Attack:
Obama Belongs on List of World's Tyrants

Poisoning Black Cities: Corporate Campaign to Ethnically Cleanse US Cities Massive Marches in Poland
Against Authoritarian Threat of Far-Right
Ethiopia’s Invisible Crisis: Land Rights Activists Kidnapped and Tortured

Global Perspectives Now Global Perspectives Now
Showing posts with label virus. Show all posts
Showing posts with label virus. Show all posts

African Ebola Survivors Share Their Stories of Recovery and Stigma (Video)

Saah Tambah describes his ebola ordeal. (Screen capture from YouTube video)
Saah Tambah describes his ebola ordeal. (Screen capture from YouTube video)
By Rakotomalala
According to the latest figures from the World Health Organization, 2,615 cases of Ebola have been reported throughout West Africa and 1,427 people have world's worst outbreak of the virus. There is no confirmed cure for Ebola, and the mortality rate for the latest outbreak sits at around 50 percent – although previous outbreaks have seen up to 90 percent of the infected perish.
died in what is being described as the

Those who have survived Ebola have remarkable tales of resilience and heroic care from local health workers, but also of sadness and rejection because of ignorance about the disease.

On Aug. 20, the WHO published a video on YouTube showcasing three of those survivors: Saah Tambah and Harrison Sakilla from Liberia and Matu Kamara from Sierra Leone.




Saah Tambah explains how he became infected and his life since his recovery:
I got the Ebola from an uncle in Koindu. I went to visit him for two nights because there was no one to take care of him. After a few days, he died and then his wife and daughter died too [..] I started vomiting and suffered from diarrhea so I went to the clinic. When I got sick, my family doubted my recovery. Thank god for the doctors. They gave me a certificate that indicates I am free of Ebola in case anyone would still doubt. 
Harrison Sakilla, 39, is from Foya in the north of Liberia. He is the first survivor from his area. He lost his mother to the disease. He says:
I got the disease caring for my mother. If someone starts to see symptoms, one should go to an Ebola health center. They will provide care and one can make it out.   
Matu Kamara, 52, says she lost her sister and her child to Ebola:
My daughter felt sick after caring from my husband's other wife. She was feeling cold. I took her to the hospital and they gave her medicine. She felt better but then later she started vomiting. She died in our arms. I felt sick and began vomiting. I went to the hospital and two days later, I felt better. We survivors from this sickness need a certificate to show to people that we had Ebola and we were treated. Do not wait to become very sick before going to the hospital.   
People who recover from the disease often face heartbreaking post-survival rejection because of a lack of understanding of how the disease spreads.Such is the story of Dr. Melvin Korkor, a doctor of Phebe hospital in Liberia. Korkor has survived Ebola but he explains that his relatives and friends were weary of touching him, as reported on the Liberian-based Front Page Africa Online:
Even though Korkor said he has been cleared of Ebola, he says that people avoid him. ‘Now, everywhere in my neighborhood, all the looks bore into me like I’m the plague,” he said. FrontPageAfrica reporter who trailed the Phebe doctor on Cuttington campus Monday observed that people left places when he showed up while friends, students and loved ones avoided his handshake or eat with him [...] “Thanks to God, I am cured. But now I have a new disease: the stigmatization that I am a victim of,” Korkor was quoted by a local radio station in Gbarnga. ‘This disease (the stigma) is worse than the fever.
Liberia is one of the four countries dealing with the outbreak, alongside Guinea, Nigeria and Sierra Leone.

Claudius Barnawolo, a Liberian physician's assistant, also beat the odds and survived Ebola. Front Page Africa Online recorded his testimony and his family members who also felt the stigma of rejection from their community:




Awareness about Ebola and how it is spread remains a challenge. Côte d'Ivoire has started an important Ebola prevention campaign, even though no cases has been detected yet. Ivorian bloggers have repurposed the viral ALS Ice Bucket Challenge for Ebola awareness using the French-language hashtag #moussercontreEbola (lather up against Ebola):

The work of lab scientists such as Dr. Korkor or Barnawolo to detect and sort out whether ailing patients have Ebola virus is also crucial in fighting the epidemic. Abdoulaye Bah, a volunteer author and translator for Global Voices, highlighted their work in Liberia (via Jina Moore):
Jeejuah, 30, and two other women, all volunteers, are cooking for 12 of the most important, but invisible, people in Liberia right now. The dozen meals are meant for the team of technicians that tests the blood of suspected Ebola patients. They visit sick peoples’ homes and overwhelmed Ebola treatment centers, sticking needles in the veins of physically unpredictable, highly contagious people. They then drive their blood back to Liberia’s only medical lab, more than an hour from the capital of Monrovia.
Evidently fighting (and surviving) Ebola will take a tremendous deal of collective effort in the affected countries, especially considering the stigma inside and outside their borders.In the context of this epidemic, it has never been more crucial for the communities to realize that they need to get organized together in this struggle or they will perish together as fools.


Reprinted with permission from Global Voices.

The Ebola Effect: Hyping the Next Bioweapon For Fear and Profit — Video Presentation

Ebola Virus. (Photo by NIAID)
Ebola Virus. (Photo by NIAID)



Documentation

Ebola: Panic or Pandemic? – An open source investigation
Time Reference: 02:05
WHO FAQ on Ebola virus disease
Time Reference: 06:55
Study suggesting that Ebola can be transmissible through the air
Time Reference: 08:18
Experts say transmission of Ebola virus by air possible
Time Reference: 08:31
Treatment of Ebola Hemorrhagic Fever with Blood Transfusions from Convalescent Patients
Time Reference: 11:00
Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates
Time Reference: 11:19
TKM-Ebola
Time Reference: 11:42
ZMapp!
Time Reference: 11:54
Toddler was ‘patient zero’ who triggered Ebola outbreak
Time Reference: 12:31
Guinea: Ebola epidemic declared, MSF launches emergency response
Time Reference: 13:00
Ebola virus disease in Guinea ( Situation as of 24 March 2014)
Time Reference: 13:25
WHO Update on June 16: 333 deaths, deadliest outbreak ever
Time Reference: 14:23
List of Ebola outbreaks
Time Reference: 14:31
Ebola: UN agency to help West Africa coordinate response to ‘unprecedented’ outbreak
Time Reference: 15:57
Health Ministers agree on priority actions to end Ebola outbreak in West Africa
Time Reference: 16:38
Treating the Ebola virus in Hamburg
Time Reference: 16:47
2002 USAMRIID procedures for treating Ebola patients
Time Reference: 18:15
August 11 update from WHO
Time Reference: 19:15
Episode 086 – Medical Martial Law
Time Reference: 21:27
George Bush speaks about medical martial law in October 2005
Time Reference: 22:25
The Model State Emergency Health Powers Act
Time Reference: 25:01
Want to Know What Martial Law over Ebola Will Look Like? Check Out What’s Happening Right Now in Africa
Time Reference: 27:27
Associated Press: Troops Deployed in Liberia
Time Reference: 28:01
Sierra Leone Deploys Troops in Ebola Crisis
Time Reference: 28:37
Ebola developments trigger CDC’s highest response level
Time Reference: 28:49
WHO declares Public Health Emergency of International Concern
Time Reference: 29:08
International Health Regulations
Time Reference: 29:28
Stephen Morrison on what the WHO can do under PHEIC
Time Reference: 30:21
Council of Europe condemns “unjustified scare” over swine flu
Time Reference: 32:34
Zmapp!
Time Reference: 34:08
ZMapp!!
Time Reference: 35:15
Zmapp!!!
Time Reference: 36:12
Aid workers flown in on suspected CIA torture plane
Time Reference: 39:51
ZMapp connections to Army, DARPA, USAMRIID
Time Reference: 40:26
Tekmira Ebola therapy placed on hold
Time Reference: 41:24
FDA allows limited use of Ebola drug. Stock spikes 45%
Time Reference: 42:01
Ebola outbreak is not an investing opportunity (yet)
Time Reference: 42:13
AIDS And Ebola Found To Use Same Mechanism To Spread In Body
Time Reference: 43:41
West Africa: What are US Biological Warfare Researchers Doing in the Ebola Zone?
Time Reference: 45:48
Sierra Leone Closes US Bioweapons Lab At Centre of Ebola Outbreak
Time Reference: 46:44
Anna Brix Thomsen on “Utopia” predictive programming
Time Reference: 49:15
joan.redmond on Russian biowarfare research
Time Reference: 50:41
Scientist Working on Gov’t Ebola Drug Joked About Culling Population with GMO Virus
Time Reference: 54:31
Professor’s population speeches unnerve some
Time Reference: 59:37
Obama Signs Executive Order to Allow Detention of Americans With ‘Respiratory Illnesses’
Time Reference: 1:00:48
Executive Order 13295: Revised List Of Quarantinable Communicable Diseases
Time Reference: 1:01:03
CDC Patent: Human ebola virus species and compositions and methods thereof
Time Reference: 1:02:38
Clock Rooting Further Demonstrates that Guinea 2014 EBOV is a Member of the Zaïre Lineage
Time Reference: 1:04:17

Scientists race to patent SARS virus
Time Reference: 1:05:15



Reprinted with permission from The Corbett Report.

Ebola Serum Politics - Pt 3: West Africans Are Finally Receiving The Same Experimental Ebola Drug Given To Europeans

Photo from European Commission DG ECHO.
Photo from European Commission DG ECHO.
By Tara Culp-Ressler
Two doctors in Liberia will be the first Africans to receive an experimental treatment for Ebola that has been previously only been used on two Americans and a Spaniard, Liberian officials announced on Monday. The decision comes on the heels of a World Health Organization panel’s ruling that it’s ethical to use the untested drug in an attempt to contain the deadly Ebola outbreak, which has claimed more than 1,000 lives in several West African nations.

There’s no cure and no vaccine for the Ebola virus, which is currently killing about 60 percent of the people who become infected with it. But an experimental Ebola drug called ZMapp, manufactured by a U.S. biotech company but not yet approved by the government, has shown promise in treating animals infected with the virus.

ZMapp was quickly given to the three Europeans who became infected with the disease while abroad — sparking concerns about the disparities in treatment emerging along geographic, economic, and racial lines. Now, the U.S. government is helping connect Liberian officials with the drug maker to ship doses into the country, but it’s still unclear how much of the limited supply Liberia will receive.

Read More

Ebola Serum Politics - Pt 2: As African Medics Die of Ebola, There's A Debate Over Who Gets the Serum

Ebola Virus Outbreaks - Source: BBC
Source: BBC


By Sarah DiLorenzo and Maria Cheng
Doctors treating a leading Sierra Leone physician who became sick with Ebola considered giving him an experimental drug but feared it could trigger a dangerous immune response and did not administer it, Doctors Without Borders said Wednesday.

The revelation came the same day that another top doctor from Sierra Leone died of the disease, fueling a debate about how to apportion a limited supply of untested drugs and vaccines and whether they are even effective. Modupeh Cole was one of the top doctors working in the Ebola isolation ward in Connaught Hospital in Freetown, Sierra Leone's capital.

Ebola has killed more than 1,000 people and sickened nearly 2,000 in the current West African outbreak that has also hit Guinea, Liberia and Nigeria. Many of the dead are health workers, who are often working with inadequate supplies and protection.

At the time the experimental treatment was being considered for Dr. Sheik Humarr Khan, his immune system was already starting to produce antibodies suggesting he might recover, Doctors Without Borders, also known by its French acronym, MSF, said in a statement Wednesday. Khan was also due to be transferred to a European hospital that would be more capable of handling any side effects that might arise with the experimental drug, it said.

In the end, the treating physicians decided igainst using the drug. They never told Khan of its existence because they felt it would be unethical to tell him of a treatment they might not use. Shortly after their decision, however, Khan's condition worsened, the statement said, and the company providing the medical evacuation decided not to transfer him. He died a few days later, on July 29.

[...]

The last known doses of ZMapp are arriving Wednesday in Liberia, where the government has said they will be given to two doctors. They would be the first Africans known to receive the treatment.

Read More

Ebola Serum Politics - Pt 1: Hundreds of Africans Die But Two Whites Get The Ebola Serum — Why?: The Ethics of Drug Distribution

Illustration provided by SouthernBreeze.
(Click to see full-sized image)
Illustration provided by SouthernBreeze.
By Arthur L. Caplan
What should happen if a massive viral outbreak appears out of nowhere and the only possible treatment is an untested drug? And who should receive it? The two American missionaries who contracted the almost-always-fatal virus in West Africa were given access to an experimental drug cocktail called ZMapp. It consists of immune-boosting monoclonal antibodies that were extracted from mice exposed to bits of Ebola DNA. Now in isolation at an Atlanta hospital, they appear to be doing well.

It’s an opportunity the 900 Africans who’ve died so far never had. Is there a case to suspend ethical norms if lives might be saved by deploying an experimental drug?

The reasons for different treatment are partly about logistics, partly about economics and, partly about a lack of any standard policy for giving out untested drugs in emergencies. Before this outbreak, ZMapp had only been tested on monkeys. Mapp, the tiny, San Diego based pharmaceutical company that makes the drug stated two years ago: “When administered one hour after infection [with Ebola], all animals survived…Two-thirds of the animals were protected even when the treatment, known as Zmapp, was administered 48 hours after infection.”

Dr. Kent Brantly and Nancy Writebol were stricken with the ebola  virus while assisting ebola victims in Africa and given an experimental  serum. Both were flown back to the US for further treatment.
Dr. Kent Brantly and Nancy Writebol were stricken with the ebola
virus while assisting ebola victims in Africa and given an experimental
serum. Both were flown back to the US for further treatment. (Screen
capture from YouTube video)
But privileged humans were always going to be the first ones to try it. ZMapp requires a lot of refrigeration and careful handling, plus close monitoring by experienced doctors and scientists—better to try it at a big urban hospital than in rural West Africa, where no such infrastructure exists.

[...]

But it’s about more than logistics. Drugs based on monoclonal antibodies usually cost a lot—at least tens of thousands of dollars. This is obviously far more than poor people in poor nations can afford to pay; and a tiny company won’t enthusiastically give away its small supply of drug for free. It is likely that if they were going to donate drugs, it would be to people who would command a lot of press attention and, thus, investors and government money for further research—which is to say, not to poor Liberians, Nigerians or Guineans.

Read More

Death Toll from Ebola in West Africa Hits 887 Says UN Health Agency

Ebola Virus Particles.
Ebola Virus Particles. (Photo by NIAID)
By Bashir Adigun
The doctor who treated a man who flew to Nigeria and died of Ebola now has contracted the disease, authorities said Monday, presenting a dire challenge to Africa's most populous nation as the regional toll for the outbreak grew to 887 dead.

As Nigerian health authorities rushed to quarantine others who had been exposed to the doctor, a special plane landed in Liberia to evacuate the second American missionary who fell ill with Ebola. Nancy Writebol, 59, is expected to arrive in Atlanta on Tuesday, where she will be treated at a special isolation ward.

The second confirmed case in Nigeria is a doctor who treated Patrick Sawyer, the Liberian-American man who died July 25 days after arriving in Nigeria from Liberia, said Nigerian Health Minister Onyebuchi Chukwu.

Three others who also treated Sawyer now show symptoms of Ebola and their test results are pending, he said. Authorities are trying to trace and quarantine others in Lagos, sub-Saharan Africa's largest city of 21 million people.

"This cluster of cases in Lagos, Nigeria is very concerning," said Dr. Tom Frieden, director of the U.S. Centers for Disease Controls and Prevention, which is dispatching 50 experienced disease control specialists to West Africa.

Read More

Ebiola Outbreak: How Did US Ebola Patients Get 'Experimental' Serum? — The 'Experimenter' Worked for the 'Defense Threat Reduction Agency'

Are 'mad scientists' working for the US military in the Ebola outbreak zone?






By Sydney Lupkin
Desperate to save the American Ebola patients in Liberia, Samaritan's Purse started researching experimental treatments last week, according to an official at the National Institutes of Health.

The organization called the Centers for Disease Control and Prevention, which referred it to an NIH employee deployed in Africa who would be familiar with the treatments.

"She was able to answer some questions and referred them to appropriate company and embassy contacts to pursue their interest in obtaining experimental product," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

He added that the NIH employee was not working in any official capacity for the NIH at the time. She was working for a team led by CDC and the Defense Threat Reduction Agency.

The experimental drug was manufactured by San Diego-based Mapp Biopharmaceuticals, according to the National Institute of Allergy and Infectious Diseases.

According to Mapp’s website, its Ebola drug is a “cocktail” of monoclonal antibodies, which had been proven to work in monkey studies.

Read More



US Biological Warfare Researchers Are in the Ebola Virus Outbreak Zone — What Are They Doing There?

Ebola in Africa, 2014.
Ebola in Africa, 2014. (Illustration from AJ Cann)

By Jon Rappoport
This is a call for an immediate, thorough, and independent investigation of Tulane University researchers (see here and here) and their Fort Detrick associates in the US biowarfare research community, who have been operating in West Africa during the past several years.
What exactly have they been doing?

Exactly what diagnostic tests have they been performing on citizens of Sierra Leone?

Why do we have reports that the government of Sierra Leone has recently told Tulane researchers to stop this testing?

Have Tulane researchers and their associates attempted any experimental treatments (e.g., injecting monoclonal antibodies) using citizens of the region? If so, what adverse events have occurred?

The research program, occurring in Sierra Leone, the Republic of Guinea, and Liberia—said to be the epicenter of the 2014 Ebola outbreak—has the announced purpose, among others, of detecting the future use of fever-viruses as bioweapons.

Is this purely defensive research? Or as we have seen in the past, is this research being covertly used to develop offensive bioweapons?

For the last several years, researchers from Tulane University have been active in the African areas where Ebola is said to have broken out in 2014.

These researchers are working with other institutions, one of which is USAMRIID, the US Army Medical Research Institute of Infectious Diseases, a well-known center for biowar research, located at Fort Detrick, Maryland.

In Sierra Leone, the Tulane group has been researching new diagnostic tests for hemorrhagic fevers.

Note: Lassa Fever, Ebola, and other labels are applied to a spectrum of illness that result in hemorrhaging.

Tulane researchers have also been investigating the use of monoclonal antibodies as a treatment for these fevers—but not on-site in Africa, according to Tulane press releases.

Here are excerpts from supporting documents.

Tulane University, Oct. 12, 2012, “Dean’s Update: Update on Lassa Fever Research” (.pdf here):

“In 2009, researchers received a five-year $7,073,538 grant from the National Institute of Health to fund the continued development of detection kits for Lassa viral hemorrhagic fever.

“Since that time, much has been done to study the disease. Dr. Robert Garry, Professor of Microbiology and Immunology, and Dr. James Robinson, Professor of Pediatrics, have been involved in the research of Lassa fever. Together the two have recently been able to create what are called human monoclonal antibodies. After isolating the B-cells from patients that have survived the disease, they have utilized molecular cloning methods to isolate the antibodies and reproduce them in the laboratory. These antibodies have been tested on guinea pigs at The University of Texas Medical Branch in Galveston and shown to help prevent them from dying of Lassa fever…

“Most recently, a new Lassa fever ward is being constructed in Sierra Leone at the Kenema Government Hospital. When finished, it will be better equipped to assist patients affected by the disease and will hopefully help to end the spread of it.” [The Kenema Hospital is one of the centers of the Ebola outbreak.]

Here is another release from Tulane University, this one dated Oct. 18, 2007. “New Test Moves Forward to Detect Bioterrorism Threats.”

“The initial round of clinical testing has been completed for the first diagnostic test kits that will aid in bioterrorism defense against a deadly viral disease. Tulane University researchers are collaborating in the project.

“Robert Garry, professor of microbiology and immunology at Tulane University, is principal investigator in a federally funded study to develop new tests for viral hemorrhagic fevers.

“Corgenix Medical Corp., a worldwide developer and marketer of diagnostic test kits, announced that the first test kits for detection of hemorrhagic fever have competed initial clinical testing in West Africa.

“The kits, developed under a $3.8 million grant awarded by the National Institutes of Health, involve work by Corgenix in collaboration with Tulane University, the U.S. Army Medical Research Institute of Infectious Diseases, BioFactura Inc. and Autoimmune Technologies.

“Clinical reports from the studies in Sierra Leone continue to show amazing results,” says Robert Garry, professor of microbiology and immunology at the Tulane University School of Medicine and principal investigator of the grant.

“We believe this remarkable collaboration will result in detection products that will truly have a meaningful impact on the healthcare in West Africa, but will also fill a badly needed gap in the bioterrorism defense.

“…The clinical studies are being conducted at the Mano River Union Lassa Fever Network in Sierra Leone. Tulane, under contract with the World Health Organization, implements the program in the Mano River Union countries (Sierra Leone, Liberia and Guinea) to develop national and regional prevention and control strategies for Lassa fever and other important regional diseases.

“Clinical testing on the new recombinant technology demonstrates that our collaboration is working,” says Douglass Simpson, president of Corgenix. “We have combined the skills of different parties, resulting in development of some remarkable test kits in a surprisingly short period of time. As a group we intend to expand this program to address other important infectious agents with both clinical health issues and threat of bioterrorism such as ebola.”

The third document is found on the Sierra Leone Ministry of Health and Sanitation Facebook page (no login required), dated July 23 at 1:35pm. It lays out emergency measures to be taken. We find this curious statement: “Tulane University to stop Ebola testing during the current Ebola outbreak.”

Why? Are the tests issuing false results? Are they frightening the population? Have Tulane researchers done something to endanger public health?

In addition to an investigation of these matters, another probe needs to be launched into all vaccine campaigns in the Ebola Zone. For example. HPV vaccine programs have been ongoing. Vials of vaccine must be tested to discover ALL ingredients. Additionally, it’s well known that giving vaccines to people whose immune systems are already severely compromised is dangerous and deadly.

Thanks to birdflu666.wordpress.com for discovering hidden elements of the Ebola story.

____________________
Jon Rappoport

The author of three explosive collections, THE MATRIX REVEALED, EXIT FROM THE MATRIX, and POWER OUTSIDE THE MATRIX, Jon was a candidate for a US Congressional seat in the 29th District of California. He maintains a consulting practice for private clients, the purpose of which is the expansion of personal creative power. Nominated for a Pulitzer Prize, he has worked as an investigative reporter for 30 years, writing articles on politics, medicine, and health for CBS Healthwatch, LA Weekly, Spin Magazine, Stern, and other newspapers and magazines in the US and Europe. Jon has delivered lectures and seminars on global politics, health, logic, and creative power to audiences around the world. You can sign up for his free emails at www.nomorefakenews.com

Reprinted with permission from Center for Research in Globalization.

Ebola Epidemic Said To Be 'Out of Control' in Africa: If AIDS Couldn't Do 'The Job' — Maybe Ebola Will

Colorized scanning electron micrograph of filamentous Ebola virus particles (blue) budding
from a chronically infected VERO E6 cell (yellow-green). (Photo from NIAID)







By Danielle Dellorto
The deadly Ebola virus outbreak in West Africa has hit "unprecedented" proportions, according to relief workers on the ground.

"The epidemic is out of control," Dr. Bart Janssens, director of operations for Doctors Without Borders, said in statement.

There have been 567 cases and 350 deaths since the epidemic began in March, according to the latest World Health Organization figures.

Ebola virus outbreaks are usually confined to remote areas, making it easier to contain. But this outbreak is different; patients have been identified in 60 locations in Guinea, Sierra Leone and Liberia.

Officials believe the wide footprint of this outbreak is partly because of the close proximity between the jungle where the virus was first identified and cities such as Conakry. The capital in Guinea has a population of 2 million and an international airport.

People are traveling without realizing they're carrying the deadly virus. It can take between two and 21 days for someone to feel sick after they've been exposed.

Ebola is a violent killer. The symptoms, at first, mimic the flu: headache, fever, tiredness. What comes next sounds like something out of a horror movie: significant diarrhea and vomiting, while the virus shuts off the blood's ability to clot.

Read More


Related Posts Plugin for WordPress, Blogger...